Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katrina Motley

Nurse Practitioner, Primary Care Indianapolis, IN Nurse Practitioner

NPI 1174934780 CMS profile 10862394

101 E 34Th St, Indianapolis, IN 46205

Open in the dashboard

General payments

$18,133

724 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katrina Motley of Indianapolis, IN is reported in the CMS Open Payments database as having received $18,133 across 724 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,570 221
2024 General $4,496 168
2023 General $4,079 158
2022 General $2,094 83
2021 General $1,894 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katrina Motley
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Katrina Motley were reported at $5,570. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Katrina Motley Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,894 $137 $39–$445 $132
2022 $2,094 $139 $44–$421 $149
2023 $4,079 $163 $53–$481 $160
2024 $4,496 $176 $54–$511 $164
2025 $5,570 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teva Pharmaceuticals USA, Inc. $3,186 100 payments
  2. ITI, Inc. $2,008 81 payments
  3. Otsuka America Pharmaceutical, Inc. $1,746 83 payments
  4. AbbVie, Inc. $1,641 82 payments
  5. Vanda Pharmaceuticals Inc. $1,328 42 payments
  6. Janssen Pharmaceuticals, Inc $1,082 39 payments
  7. Alkermes, Inc. $961 44 payments
  8. E.R. Squibb & Sons, L.L.C. $701 22 payments
  9. Neurocrine Biosciences, Inc. $667 18 payments
  10. Lundbeck LLC $554 35 payments
  11. Other $4,259 178 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,452 706 payments
  2. Education $681 18 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA $1,440 63 payments
  2. FANAPT $1,328 42 payments
  3. Austedo XR $1,304 52 payments
  4. REXULTI $1,110 56 payments
  5. VRAYLAR $1,012 51 payments
  6. HETLIOZ $935 38 payments
  7. LYBALVI $766 39 payments
  8. UZEDY $754 24 payments
  9. INVEGA SUSTENNA $704 29 payments
  10. INGREZZA $667 18 payments
  11. Other $11,940 543 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$44,657

Medicare's payments for the services billed

Medicare patients

193

Average age 55

Services billed

742

93 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Depression 67%
Diabetes 44%
Chronic kidney disease 30%
Arthritis 25%
Heart failure 24%
COPD 22%
Alzheimer's or dementia 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
$538 — —
FANAPT
$455 — —
REXULTI
$448 — —
UZEDY
$306 — —
SPRAVATO
$160 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

724 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record